JP5552262B2 - 肺疾患の治療に用いられる気体製剤 - Google Patents
肺疾患の治療に用いられる気体製剤 Download PDFInfo
- Publication number
- JP5552262B2 JP5552262B2 JP2009117078A JP2009117078A JP5552262B2 JP 5552262 B2 JP5552262 B2 JP 5552262B2 JP 2009117078 A JP2009117078 A JP 2009117078A JP 2009117078 A JP2009117078 A JP 2009117078A JP 5552262 B2 JP5552262 B2 JP 5552262B2
- Authority
- JP
- Japan
- Prior art keywords
- pulmonary
- inhalation
- gas
- disease
- carbon monoxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 40
- 208000019693 Lung disease Diseases 0.000 title claims description 17
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 138
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 138
- 239000007789 gas Substances 0.000 claims description 77
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 52
- 238000002664 inhalation therapy Methods 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 102000001554 Hemoglobins Human genes 0.000 claims description 19
- 108010054147 Hemoglobins Proteins 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 230000001684 chronic effect Effects 0.000 claims description 17
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 13
- 210000001147 pulmonary artery Anatomy 0.000 claims description 13
- 210000001552 airway epithelial cell Anatomy 0.000 claims description 12
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 11
- 208000028831 congenital heart disease Diseases 0.000 claims description 11
- 206010021143 Hypoxia Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000002685 pulmonary effect Effects 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 8
- 238000002640 oxygen therapy Methods 0.000 claims description 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000027932 Collagen disease Diseases 0.000 claims description 6
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 6
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 6
- 208000003287 Eisenmenger Complex Diseases 0.000 claims description 6
- 208000020686 Eisenmenger syndrome Diseases 0.000 claims description 6
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 6
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims description 6
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 claims description 6
- 230000001146 hypoxic effect Effects 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 6
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims description 6
- 201000002859 sleep apnea Diseases 0.000 claims description 6
- 201000003130 ventricular septal defect Diseases 0.000 claims description 6
- 206010024119 Left ventricular failure Diseases 0.000 claims description 5
- 206010047163 Vasospasm Diseases 0.000 claims description 5
- 206010061005 Cardiac myxoma Diseases 0.000 claims description 4
- 206010009126 Chronic respiratory failure Diseases 0.000 claims description 4
- 241000430519 Human rhinovirus sp. Species 0.000 claims description 4
- 206010034487 Pericarditis constrictive Diseases 0.000 claims description 4
- 208000000839 constrictive pericarditis Diseases 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 206010037340 Pulmonary artery thrombosis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 230000001746 atrial effect Effects 0.000 claims description 2
- 208000025339 heart septal defect Diseases 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 41
- 238000002474 experimental method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 206010013975 Dyspnoeas Diseases 0.000 description 18
- 208000000059 Dyspnea Diseases 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000009798 acute exacerbation Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 5
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 5
- 208000035478 Interatrial communication Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 208000013914 atrial heart septal defect Diseases 0.000 description 5
- 206010003664 atrial septal defect Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002040 relaxant effect Effects 0.000 description 5
- 239000000779 smoke Substances 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 238000004868 gas analysis Methods 0.000 description 4
- 229940076144 interleukin-10 Drugs 0.000 description 4
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010007269 Carcinogenicity Diseases 0.000 description 3
- 108010078321 Guanylate Cyclase Proteins 0.000 description 3
- 102000014469 Guanylate cyclase Human genes 0.000 description 3
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 3
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 231100000260 carcinogenicity Toxicity 0.000 description 3
- 230000007670 carcinogenicity Effects 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 230000036593 pulmonary vascular resistance Effects 0.000 description 3
- 230000004202 respiratory function Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000016761 Haem oxygenases Human genes 0.000 description 2
- 108050006318 Haem oxygenases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241000710122 Rhinovirus B14 Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010050701 Congenital pulmonary hypertension Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 101150004928 bun gene Proteins 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000037 inhalation toxicity test Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、数十から数百ppmの低濃度一酸化炭素を含む気体製剤を用いて肺高血圧症の患者への治療法とすることを特徴とする。
以下、本発明に係る気体製剤を用いた臨床実験例について説明する。なお、本臨床実験の目的は、本発明にかかるCO吸入療法による肺高血圧症における呼吸困難感の改善効果、肺高血圧に対する血圧減少効果、血小板凝集抑制効果、血液凝固因子への影響、肺機能への影響、血清過酸化脂質(活性酸素への影響)、抗炎症性サイトカインであるインターロイキン10 (IL-10)への影響の検討である。
以下、本臨床実験例の評価法を説明する。
以下、[表4]、[表5]及び[表6]を参照して本臨床実験例の結果を示す。
上記臨床実験において、発明者らは12時間の吸入で2〜3日に渡るCO吸入の臨床効果(息切れ感の改善)を認めている。
102 一酸化炭素及び窒素用ボンベ
103 鼻カヌラ
104 患者
Claims (5)
- ウイルス性呼吸器感染症を予防するための気体吸入療法、又は、肺高血圧症を伴う疾患を有する患者の運動耐性能を向上させるための気体吸入療法に用いる気体製剤であって、
前記ウイルス性呼吸器感染症には、炎症性肺疾患を有する患者におけるヒトライノウイルス14型(RV14)の気道上皮細胞への感染であり、
前記肺高血圧症を伴う疾患には、原発性肺高血圧症、慢性的弁膜症、陳旧性心筋梗塞や拡張型心筋症を含む高度左心不全、収縮性心膜炎、左房粘液腫、心房中隔欠損症や心室中隔欠損症を含む心内左−右短絡疾患、動脈管開損症、末梢性動静脈短絡、先天性心疾患によるEisenmenger症候群、肺血管炎、膠原病に伴う肺高血圧症、低酸素性肺血管攣縮、陳旧性肺結核、間質性肺炎、肺血栓塞栓症、各種癌の肺動脈転移、閉塞性睡眠時無呼吸症候群、慢性閉塞性肺疾患のいずれかが含まれ、
当該気体製剤には少なくとも一酸化炭素が含まれ、
患者が吸入する前記気体製剤の前記一酸化炭素の濃度は、20ppm以上300ppm未満である
ことを特徴とする気体製剤。 - 患者が吸入する前記気体製剤の前記一酸化炭素の濃度は、40ppm以上100ppm未満である
ことを特徴とする請求項1記載の気体製剤。 - 前記気体製剤には、さらに酸素及び窒素が含まれ、前記一酸化炭素の濃度は、当該酸素及び窒素に対する濃度であり、
在宅酸素療法で用いられる量と同量の酸素が一酸化炭素とともに患者に吸入される
ことを特徴とする請求項1又は2記載の気体製剤。 - 前記疾患には、さらに、肺性心、肺高血圧症による右心負荷、慢性炎症に伴う肺動脈血栓症、慢性呼吸不全、又は癌終末期が含まれる
ことを特徴とする請求項1記載の気体製剤。 - 前記気体製剤はさらに、動脈血一酸化炭素ヘモグロビン濃度を安全に増加させるための気体吸入療法に用いられる
ことを特徴とする請求項1記載の気体製剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009117078A JP5552262B2 (ja) | 2009-05-13 | 2009-05-13 | 肺疾患の治療に用いられる気体製剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009117078A JP5552262B2 (ja) | 2009-05-13 | 2009-05-13 | 肺疾患の治療に用いられる気体製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010265205A JP2010265205A (ja) | 2010-11-25 |
JP5552262B2 true JP5552262B2 (ja) | 2014-07-16 |
Family
ID=43362542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009117078A Active JP5552262B2 (ja) | 2009-05-13 | 2009-05-13 | 肺疾患の治療に用いられる気体製剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5552262B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6112756B2 (ja) * | 2011-06-17 | 2017-04-12 | フクダ電子株式会社 | 一酸化炭素投与システム |
JP6112757B2 (ja) * | 2011-06-17 | 2017-04-12 | フクダ電子株式会社 | 一酸化炭素投与システム |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200401622A1 (ru) * | 2002-06-05 | 2005-06-30 | Йейл Юниверсити | Способы лечения ангиогенеза, роста опухолей и метастазов |
-
2009
- 2009-05-13 JP JP2009117078A patent/JP5552262B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010265205A (ja) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vivó et al. | Initial evaluation and management of the critical burn patient | |
Li et al. | Limb remote ischemic preconditioning attenuates lung injury after pulmonary resection under propofol–remifentanil anesthesia: a randomized controlled study | |
Araneda et al. | Lung oxidative damage by hypoxia | |
Francis et al. | Protective and detrimental effects of sodium sulfide and hydrogen sulfide in murine ventilator-induced lung injury | |
JP2020002144A (ja) | 小児における急性呼吸促迫症候群の治療のための吸入一酸化窒素ガスを使用する方法 | |
US20170239289A1 (en) | Treatment of inflammation, respiratory tract infections and cystic fibrosis | |
JP4585765B2 (ja) | 壊死性腸炎の治療方法 | |
JP2019501965A (ja) | 一酸化窒素を含むガスを投与するための方法及び装置 | |
Ekkernkamp et al. | Spot check analysis of gas exchange: invasive versus noninvasive methods | |
Türkan et al. | The effect of sevoflurane and desflurane on markers of oxidative status in erythrocyte | |
Roca et al. | Mechanical ventilation induces changes in exhaled breath condensate of patients without lung injury | |
JP2019123754A (ja) | 心肺血行動態を改善するための無機亜硝酸塩 | |
JP5552262B2 (ja) | 肺疾患の治療に用いられる気体製剤 | |
Morimatsu et al. | An increase in exhaled CO concentration in systemic inflammation/sepsis | |
Tsuchiya et al. | Interrelation between oxygen tension and nitric oxide in the respiratory system | |
Vuong et al. | Association between exogenous nitric oxide given during cardiopulmonary bypass and the incidence of postoperative kidney injury in children | |
Manuilov et al. | Evaluation of the efficiency of oxygen–helium therapy for patients with Covid-19-associated pneumonia | |
Knight et al. | Understanding the effects of oxygen administration in haemorrhagic shock | |
Aliasgharpour et al. | Effect of Incentive Spirometry on Pulmonary Function Tests in Patients Undergoing Hemodialysis: A Randomized Clinical Trials | |
Polito et al. | Adrenocortical cell tolerance to lipopolysaccharide: a new mechanism for critical illness related corticosteroid insufficiency | |
Schober et al. | Cardiopulmonary bypass increases endogenous carbon monoxide production | |
Hocagil et al. | Does Simple Face Mask or Diffuser Mask Matter in the First Hour Treatment of Carbon Monoxide Intoxication? A Prospective Randomized Clinical Study | |
ALAGHA et al. | The effects of on-pump and off-pump coronary artery bypass surgery on oxidative stress and cerebral oxygenation: a prospective observational study | |
RU2797218C1 (ru) | Способ ингаляционной седации при тяжелом ишемическом инсульте | |
Güneş et al. | High-dose hyperbaric oxygen treatment in a carbon monoxide intoxication patient attending acute smoke inhalation and burn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120509 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120514 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140526 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5552262 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |